Study sites have a tremendous influence on how, when, and where clinical trials take place. They’re the ones training personnel, allocating staff, enrolling participants, managing paperwork, and so much more. So it makes sense that when sponsors need to make important decisions—like which CRO to choose—sites will most certainly have an opinion.
Racial and ethnic minorities are under-represented in clinical trials. We’ll discuss who is participating in clinical trials, why diversity is important, and solutions on what sponsors, CROs,
Interim analyses (IA) are an essential part of clinical trials that—as a form of adaptive design—can help sponsors make informed decisions about whether to keep a trial going or discontinue it entirely. Join Rho’s Brett Gordon, Ben Vaughn, and Scott Mollan for this Q&A roundtable that will cover some of the most frequently asked questions they get from pharma companies about interim analysis.
If you were born during the Spanish flu of 1918, you had a 2-3x higher risk of Parkinson’s. If COVID-19 caused the same viral damage, what does that mean for all of us? In this webinar, study author Pete Schmidt, PhD (Rho) and Mark Stacy,
Nine out of 10 clinical trials for new drugs fail; Oncology drugs have a 3.4 percent probability of succeeding. Still, cancer drugs can and are being commercialized. From 2003 to 2020, 124 oncology therapies were approved by FDA. What makes this possible? Knowing the key factors to consider at each juncture
Patient advocacy is vital for advancement in managing disease. We met with Chandrabali Ghose-Paul, Chief Scientific Officer, Emily’s Entourage and Gary Joyner, Chairman Emeritus, Board of Directors, Primary Ciliary Dyskinesia (PCD) Foundation to discuss the role of patient advocacy groups
Personalized medicine has a complexity problem. In Parkinson’s, this complexity problem is far-reaching and access-limiting. Dr. Schmidt presents his insight from bench research, clinical trials, and care workflow optimization to explore how optimized
It’s in the collective best interest of research sponsors, participants, and sites to get clinical trials up and running faster and with the right safety surveillance mechanisms in place. But all too often, challenges and complexities stand in the way of efficient trial activation, enrollment, and post-activation monitoring.
Study start-up sets the foundation for success of your clinical trial. There are many considerations for vendor selection and partnerships during development and start-up. With these come challenges: complex protocols, gaps in site expectations, problems with enrollment and retention,
Expanded Access can be leveraged to advance and even accelerate clinical development of treatments for serious or life-threatening conditions. This webinar examin
© 2025 Rho, Inc. All rights reserved.
